Management of Hepatitis C Infection
Summary
- Voxilaprevir is an NS3/NS4A protease inhibitor
- Voxilaprevir, coformulated with sofosbuvir and velpatasvir, is approved by the FDA for 12-week retreatment of genotypes 1-6 HCV after previous failure of an NS5A inhibitor–containing regimen and genotypes 1a or 3 after previous failure of a sofosbuvir-containing regimen[FDA Sofosbuvir Velpatasvir Voxilaprevir]
- The EMA has approved sofosbuvir/velpatasvir/voxilaprevir for treatment of genotypes 1-6 HCV infection in both DAA-naive and DAA-experienced populations[EMA Sofosbuvir Velpatasvir Voxilaprevir]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment